The therapeutic landscape for patients battling relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has been fundamentally revolutionized with the emergence of EPKINLY (epcoritamab), a pioneering CD20xCD3 bispecific antibody that has redefined therapeutic possibilities for this aggressive hematologic malignancy. This innovative treatment modality represents the...